Marina Siebert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marina Siebert has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Andreia Rocha
Department of Psychiatry, School of Medicine, University of Pittsburgh
3 shared publications - Carolina Soares
Department of Psychiatry, School of Medicine, University of Pittsburgh, PA
3 shared publications - Diogo Onofre Souza
Universidade Federal do Rio Grande do Sul
3 shared publications - Eduardo Rigon Zimmer
Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
3 shared publications - Gabriela Lazzarotto
Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul Brazil
3 shared publications - Ida Vanessa Doederlein Schwartz
Department of Genetics, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
3 shared publications
Latest Publications
- 19 July 2024
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 40 (4) , e12990
Modulation of gene expression in skin wound healing by photobiomodulation therapy: A systematic review in vivo studies
Background: Wound healing is a multistep process involving coordinated responses of a variety of cell types, cytokines, growth factors, and extracellular matrix (ECM) components leading to the physiological restoration of tissue integrity. Photobiomodulation therapy (PBMT) has been highlighted as an approach to improve the healing process, nonetheless at the molecular level, the effects of PBMT are not entirely understood.Aim: To systematically review publications that investigated gene expression after PBMT during in vivo skin repair.Methods: An electronic search was undertaken in Medline Ovid (Wolters Kluwer), PubMed (National Library of Medicine), Web of Science (Thomson Reuters), Scopus (Elsevier), Embase, and LILACS databases. The search strategy was conducted from the terms: low‐level light therapy, gene expression, and wound healing and their synonyms. The databases were consulted in December 2023 and no publication year limit was used.Results: Eleven studies were included in this review and the expression of 186 genes was evaluated. PBMT modified the expression of several targets genes studied, such as down‐regulation of genes related to extracellular matrix proteases (MMP2andMMP9) and pro‐inflammatory cytokines (IL10andIL6) and up‐regulation ofDNMT3AandBFGF.Conclusion: This review demonstrates that PBMT is capable of regulating gene expression during wound healing. Most evidence showed a positive impact of PBMT in regulating genes linked to inflammatory cytokines improving skin wound healing. Yet, the effects of PBMT in genes involved in other mechanisms still need to be better understood.
- 19 July 2024
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 40 (4) , e12990
Modulation of gene expression in skin wound healing by photobiomodulation therapy: A systematic review in vivo studies
Background: Wound healing is a multistep process involving coordinated responses of a variety of cell types, cytokines, growth factors, and extracellular matrix (ECM) components leading to the physiological restoration of tissue integrity. Photobiomodulation therapy (PBMT) has been highlighted as an approach to improve the healing process, nonetheless at the molecular level, the effects of PBMT are not entirely understood.Aim: To systematically review publications that investigated gene expression after PBMT during in vivo skin repair.Methods: An electronic search was undertaken in Medline Ovid (Wolters Kluwer), PubMed (National Library of Medicine), Web of Science (Thomson Reuters), Scopus (Elsevier), Embase, and LILACS databases. The search strategy was conducted from the terms: low‐level light therapy, gene expression, and wound healing and their synonyms. The databases were consulted in December 2023 and no publication year limit was used.Results: Eleven studies were included in this review and the expression of 186 genes was evaluated. PBMT modified the expression of several targets genes studied, such as down‐regulation of genes related to extracellular matrix proteases (MMP2andMMP9) and pro‐inflammatory cytokines (IL10andIL6) and up‐regulation ofDNMT3AandBFGF.Conclusion: This review demonstrates that PBMT is capable of regulating gene expression during wound healing. Most evidence showed a positive impact of PBMT in regulating genes linked to inflammatory cytokines improving skin wound healing. Yet, the effects of PBMT in genes involved in other mechanisms still need to be better understood.
- 2 February 2024
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 39 (4) , 577-587
Identification of metabolic pathways and key genes associated with atypical parkinsonism using a systems biology approach
Atypical parkinsonism (AP) is a group of complex neurodegenerative disorders with marked clinical and pathophysiological heterogeneity. The use of systems biology tools may contribute to the characterization of hub-bottleneck genes, and the identification of its biological pathways to broaden the understanding of the bases of these disorders. A systematic search was performed on the DisGeNET database, which integrates data from expert curated repositories, GWAS catalogues, animal models and the scientific literature. The tools STRING 11.0 and Cytoscape 3.8.2 were used for analysis of protein-protein interaction (PPI) network. The PPI network topography analyses were performed using the CytoHubba 0.1 plugin for Cytoscape. The hub and bottleneck genes were inserted into 4 different sets on the InteractiveVenn. Additional functional enrichment analyses were performed to identify Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and gene ontology for a described set of genes. The systematic search in the DisGeNET database identified 485 genes involved with Atypical Parkinsonism. Superimposing these genes, we detected a total of 31 hub-bottleneck genes. Moreover, our functional enrichment analyses demonstrated the involvement of these hub-bottleneck genes in 3 major KEGG pathways. We identified 31 highly interconnected hub-bottleneck genes through a systems biology approach, which may play a key role in the pathogenesis of atypical parkinsonism. The functional enrichment analyses showed that these genes are involved in several biological processes and pathways, such as the glial cell development, glial cell activation and cognition, pathways were related to Alzheimer disease and Parkinson disease. As a hypothesis, we highlight as possible key genes for AP the MAPT (microtubule associated protein tau), APOE (apolipoprotein E), SNCA (synuclein alpha) and APP (amyloid beta precursor protein) genes.
- 2 February 2024
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 39 (4) , 577-587
Identification of metabolic pathways and key genes associated with atypical parkinsonism using a systems biology approach
Atypical parkinsonism (AP) is a group of complex neurodegenerative disorders with marked clinical and pathophysiological heterogeneity. The use of systems biology tools may contribute to the characterization of hub-bottleneck genes, and the identification of its biological pathways to broaden the understanding of the bases of these disorders. A systematic search was performed on the DisGeNET database, which integrates data from expert curated repositories, GWAS catalogues, animal models and the scientific literature. The tools STRING 11.0 and Cytoscape 3.8.2 were used for analysis of protein-protein interaction (PPI) network. The PPI network topography analyses were performed using the CytoHubba 0.1 plugin for Cytoscape. The hub and bottleneck genes were inserted into 4 different sets on the InteractiveVenn. Additional functional enrichment analyses were performed to identify Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and gene ontology for a described set of genes. The systematic search in the DisGeNET database identified 485 genes involved with Atypical Parkinsonism. Superimposing these genes, we detected a total of 31 hub-bottleneck genes. Moreover, our functional enrichment analyses demonstrated the involvement of these hub-bottleneck genes in 3 major KEGG pathways. We identified 31 highly interconnected hub-bottleneck genes through a systems biology approach, which may play a key role in the pathogenesis of atypical parkinsonism. The functional enrichment analyses showed that these genes are involved in several biological processes and pathways, such as the glial cell development, glial cell activation and cognition, pathways were related to Alzheimer disease and Parkinson disease. As a hypothesis, we highlight as possible key genes for AP the MAPT (microtubule associated protein tau), APOE (apolipoprotein E), SNCA (synuclein alpha) and APP (amyloid beta precursor protein) genes.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
Association between glial and synaptic fluid biomarkers and brain [18F]FDG‐PET signal
Background: Beyond the hypometabolic signature, indexed by [18F]FDG‐PET imaging, seen in the brain of Alzheimer’s disease (AD) patients, a transient brain glucose hypermetabolism has been recently identified in the early stages of AD. The cellular source of this dual metabolic response remains controversial, with glial cells gaining a lot of attention. In light of this, whether glial and synaptic fluid biomarkers are associated with [18F]FDG‐PET signal in the early stages of AD remains debatable. Thus, we evaluated the association of astrocyte, microglial and synaptic fluid biomarkers with [18F]FDG‐PET signal in an AD rat model.Method: [18F]FDG‐PET imaging was conducted in ten‐month‐old (early amyloid stage) APP/PS1 (TgF344‐AD, n = 8‐17) and wild‐type (WT, n = 8‐15) rats. Glial (GFAP and sTREM2), synaptic (neurogranin), and amyloid biomarkers (Aβ1‐40 and Aβ1‐42) were quantified in the cerebrospinal fluid (CSF) and plasma through a multiplex immunoassay. T‐statistical maps of brain [18F]FDG‐PET and those fluid biomarkers were conducted at the voxel level using RMINC. Differences were considered statistically significant at p2).Result: A large hypermetabolic cluster was identified in ten‐month‐old TgF344‐AD (Fig. 1AB, local maxima, t(13) = 4.28). We found positive correlations between CSF TREM2 and brain [18F]FDG‐PET signal (Fig. 2AC, local maxima, t(13) = 4.12). In addition, we identified a positive correlation between plasma GFAP and brain [18F]FDG‐PET signal (Fig. 2BC, local maxima, t(13) = 10.62). Plasma TREM2, CSF GFAP, and plasma neurogranin did not associate with brain glucose metabolism.Conclusion: Our findings suggest that CSF TREM2 and plasma GFAP are associated with brain metabolism before amyloid load reaches a plateau. Stronger association of plasma GFAP, rather than CSF GFAP, with brain pathology corroborates cross‐sectional human studies. One could argue that [18F]FDG‐PET hypermetabolism identified is likely a response to astrocyte and microglial changes.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
Open AccessAssociation between glial and synaptic fluid biomarkers and brain [18F]FDG‐PET signal
Background: Beyond the hypometabolic signature, indexed by [18F]FDG‐PET imaging, seen in the brain of Alzheimer’s disease (AD) patients, a transient brain glucose hypermetabolism has been recently identified in the early stages of AD. The cellular source of this dual metabolic response remains controversial, with glial cells gaining a lot of attention. In light of this, whether glial and synaptic fluid biomarkers are associated with [18F]FDG‐PET signal in the early stages of AD remains debatable. Thus, we evaluated the association of astrocyte, microglial and synaptic fluid biomarkers with [18F]FDG‐PET signal in an AD rat model.Method: [18F]FDG‐PET imaging was conducted in ten‐month‐old (early amyloid stage) APP/PS1 (TgF344‐AD, n = 8‐17) and wild‐type (WT, n = 8‐15) rats. Glial (GFAP and sTREM2), synaptic (neurogranin), and amyloid biomarkers (Aβ1‐40 and Aβ1‐42) were quantified in the cerebrospinal fluid (CSF) and plasma through a multiplex immunoassay. T‐statistical maps of brain [18F]FDG‐PET and those fluid biomarkers were conducted at the voxel level using RMINC. Differences were considered statistically significant at p2).Result: A large hypermetabolic cluster was identified in ten‐month‐old TgF344‐AD (Fig. 1AB, local maxima, t(13) = 4.28). We found positive correlations between CSF TREM2 and brain [18F]FDG‐PET signal (Fig. 2AC, local maxima, t(13) = 4.12). In addition, we identified a positive correlation between plasma GFAP and brain [18F]FDG‐PET signal (Fig. 2BC, local maxima, t(13) = 10.62). Plasma TREM2, CSF GFAP, and plasma neurogranin did not associate with brain glucose metabolism.Conclusion: Our findings suggest that CSF TREM2 and plasma GFAP are associated with brain metabolism before amyloid load reaches a plateau. Stronger association of plasma GFAP, rather than CSF GFAP, with brain pathology corroborates cross‐sectional human studies. One could argue that [18F]FDG‐PET hypermetabolism identified is likely a response to astrocyte and microglial changes.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Association between plasma inflammatory biomarkers and [18F]FDG‐PET signal in a transgenic amyloid rat model
Background: Neuroinflammation is thought to play an important role in the pathogenesis of Alzheimer’s disease (AD). It has recently been demonstrated that [18F]FDG positron emission tomography (PET) signal is sensitive to central inflammatory changes in AD. However, it is unknown whether blood cytokines, which are important signaling molecules that regulate the peripheral inflammatory process, are associated with the cerebral [18F]FDG‐PET signal. In this work, we aimed to investigate whether plasma cytokines are associated with brain glucose metabolism in a transgenic amyloid rat model.Method: Brain metabolism of 4‐ and 10‐month‐old wild‐type (WT) and APP/PS1 rats (TgF344‐AD) were assessed with [18F]FDG‐PET imaging. Plasma inflammatory markers (IFN‐γ, IL‐1α, IL‐1β, IL‐6, IL‐10 and TNF‐α) were measured by multiplex immunoassay. [18F]FDG‐SUVr was calculated with pons as the reference region. Correlation between inflammatory markers and [18F]FDG‐PET signal was conducted at the voxel level (RMINC; p2).Result: At 4 months, IL‐10 levels significantly associate with [18F]FDG‐PET signal in the frontal and temporoparietal cortices (FCx and TPCx) and hippocampus (Fig1A), whereas other biomarkers present only small clusters associated with [18F]FDG‐PET signal (Fig1A). At 10 months, a positive association with [18F]FDG‐PET was found between IL‐1α and IL‐1β at FCx and TPCx, while IL‐10 showed a positive correlation at the TPCx (Fig1B). Additionality, IFN‐γ and TNF‐α presented small correlation clusters at the TPCx, and IL‐6 at the TPCx and CxF (Fig1B).Conclusion: At the pre‐amyloid plaque stage, only an anti‐inflammatory cytokine, IL‐10, presented positive associations with brain glucose metabolism. However, multiple pro‐inflammatory cytokines correlated with brain glucose metabolism at the amyloid plaque stage. These findings suggest a dual peripheral inflammatory response impacting brain metabolism, which can be associated with amyloid species and deposition.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Open AccessAssociation between plasma inflammatory biomarkers and [18F]FDG‐PET signal in a transgenic amyloid rat model
Background: Neuroinflammation is thought to play an important role in the pathogenesis of Alzheimer’s disease (AD). It has recently been demonstrated that [18F]FDG positron emission tomography (PET) signal is sensitive to central inflammatory changes in AD. However, it is unknown whether blood cytokines, which are important signaling molecules that regulate the peripheral inflammatory process, are associated with the cerebral [18F]FDG‐PET signal. In this work, we aimed to investigate whether plasma cytokines are associated with brain glucose metabolism in a transgenic amyloid rat model.Method: Brain metabolism of 4‐ and 10‐month‐old wild‐type (WT) and APP/PS1 rats (TgF344‐AD) were assessed with [18F]FDG‐PET imaging. Plasma inflammatory markers (IFN‐γ, IL‐1α, IL‐1β, IL‐6, IL‐10 and TNF‐α) were measured by multiplex immunoassay. [18F]FDG‐SUVr was calculated with pons as the reference region. Correlation between inflammatory markers and [18F]FDG‐PET signal was conducted at the voxel level (RMINC; p2).Result: At 4 months, IL‐10 levels significantly associate with [18F]FDG‐PET signal in the frontal and temporoparietal cortices (FCx and TPCx) and hippocampus (Fig1A), whereas other biomarkers present only small clusters associated with [18F]FDG‐PET signal (Fig1A). At 10 months, a positive association with [18F]FDG‐PET was found between IL‐1α and IL‐1β at FCx and TPCx, while IL‐10 showed a positive correlation at the TPCx (Fig1B). Additionality, IFN‐γ and TNF‐α presented small correlation clusters at the TPCx, and IL‐6 at the TPCx and CxF (Fig1B).Conclusion: At the pre‐amyloid plaque stage, only an anti‐inflammatory cytokine, IL‐10, presented positive associations with brain glucose metabolism. However, multiple pro‐inflammatory cytokines correlated with brain glucose metabolism at the amyloid plaque stage. These findings suggest a dual peripheral inflammatory response impacting brain metabolism, which can be associated with amyloid species and deposition.
- Open Access
- 24 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S10)
Association between glial and synaptic fluid biomarkers and brain [18F]FDG‐PET signal
Background: Beyond the hypometabolic signature, indexed by [18F]FDG‐PET imaging, seen in the brain of Alzheimer’s disease (AD) patients, a transient brain glucose hypermetabolism has been recently identified in the early stages of AD. The cellular source of this dual metabolic response remains controversial, with glial cells gaining a lot of attention. In light of this, whether glial and synaptic fluid biomarkers are associated with [18F]FDG‐PET signal in the early stages of AD remains debatable. Thus, we evaluated the association of astrocyte, microglial and synaptic fluid biomarkers with [18F]FDG‐PET signal in an AD rat model.Method: [18F]FDG‐PET imaging was conducted in ten‐month‐old (early amyloid stage) APP/PS1 (TgF344‐AD, n = 8‐17) and wild‐type (WT, n = 8‐15) rats. Glial (GFAP and sTREM2), synaptic (neurogranin), and amyloid biomarkers (Aß1‐40 and Aß1‐42) were quantified in the cerebrospinal fluid (CSF) and plasma through a multiplex immunoassay. T‐statistical maps of brain [18F]FDG‐PET and those fluid biomarkers were conducted at the voxel level using RMINC. Differences were considered statistically significant at p2).Result: A large hypermetabolic cluster was identified in ten‐month‐old TgF344‐AD (Fig. 1AB, local maxima, t(13) = 4.28). We found positive correlations between CSF TREM2 and brain [18F]FDG‐PET signal (Fig. 2AC, local maxima, t(13) = 4.12). In addition, we identified a positive correlation between plasma GFAP and brain [18F]FDG‐PET signal (Fig. 2BC, local maxima, t(13) = 10.62). Plasma TREM2, CSF GFAP, and plasma neurogranin did not associate with brain glucose metabolism.Conclusion: Our findings suggest that CSF TREM2 and plasma GFAP are associated with brain metabolism before amyloid load reaches a plateau. Stronger association of plasma GFAP, rather than CSF GFAP, with brain pathology corroborates cross‐sectional human studies. One could argue that [18F]FDG‐PET hypermetabolism identified is likely a response to astrocyte and microglial changes.
- 24 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S10)
Open AccessAssociation between glial and synaptic fluid biomarkers and brain [18F]FDG‐PET signal
Background: Beyond the hypometabolic signature, indexed by [18F]FDG‐PET imaging, seen in the brain of Alzheimer’s disease (AD) patients, a transient brain glucose hypermetabolism has been recently identified in the early stages of AD. The cellular source of this dual metabolic response remains controversial, with glial cells gaining a lot of attention. In light of this, whether glial and synaptic fluid biomarkers are associated with [18F]FDG‐PET signal in the early stages of AD remains debatable. Thus, we evaluated the association of astrocyte, microglial and synaptic fluid biomarkers with [18F]FDG‐PET signal in an AD rat model.Method: [18F]FDG‐PET imaging was conducted in ten‐month‐old (early amyloid stage) APP/PS1 (TgF344‐AD, n = 8‐17) and wild‐type (WT, n = 8‐15) rats. Glial (GFAP and sTREM2), synaptic (neurogranin), and amyloid biomarkers (Aß1‐40 and Aß1‐42) were quantified in the cerebrospinal fluid (CSF) and plasma through a multiplex immunoassay. T‐statistical maps of brain [18F]FDG‐PET and those fluid biomarkers were conducted at the voxel level using RMINC. Differences were considered statistically significant at p2).Result: A large hypermetabolic cluster was identified in ten‐month‐old TgF344‐AD (Fig. 1AB, local maxima, t(13) = 4.28). We found positive correlations between CSF TREM2 and brain [18F]FDG‐PET signal (Fig. 2AC, local maxima, t(13) = 4.12). In addition, we identified a positive correlation between plasma GFAP and brain [18F]FDG‐PET signal (Fig. 2BC, local maxima, t(13) = 10.62). Plasma TREM2, CSF GFAP, and plasma neurogranin did not associate with brain glucose metabolism.Conclusion: Our findings suggest that CSF TREM2 and plasma GFAP are associated with brain metabolism before amyloid load reaches a plateau. Stronger association of plasma GFAP, rather than CSF GFAP, with brain pathology corroborates cross‐sectional human studies. One could argue that [18F]FDG‐PET hypermetabolism identified is likely a response to astrocyte and microglial changes.
- 28 August 2023
- Published by Wiley in Oral Diseases
- Vol. 30 (4) , 2722-2727
Salivary microbiome and oral mucositis in HSCT recipients: A pilot study
- 28 August 2023
- Published by Wiley in Oral Diseases
- Vol. 30 (4) , 2722-2727
Salivary microbiome and oral mucositis in HSCT recipients: A pilot study
- 15 January 2023
- Published by Wiley in Clinical Genetics
- Vol. 103 (5) , 580-584
Copy number variations in SPAST and ATL1 are rare among Brazilians
Copy number variations (CNV) may represent a significant proportion of SPG4 and SPG3A diagnosis, the most frequent autosomal dominant subtypes of hereditary spastic paraplegias (HSP). We aimed to assess the frequency of CNVs in SPAST and ATL1 and to update the molecular epidemiology of HSP families in southern Brazil. A cohort study that included 95 Brazilian index cases with clinical suspicion of HSP was conducted between April 2011 and September 2022. Multiplex Ligation Dependent Probe Amplification (MLPA) was performed in 41 cases without defined diagnosis by different massive parallel sequencing techniques (MPS). Diagnosis was obtained in 57/95 (60%) index cases, 15/57 (26.3%) being SPG4. Most frequent autosomal recessive HSP subtypes were SPG7 followed by SPG11, SPG76 and cerebrotendinous xanthomatosis. No CNVs in SPAST and ATL1 were found. Copy number variations are rare among SPG4 and SPG3A families in Brazil. Considering the possibility of CNVs detection by specific algorithms with MPS data, we consider that this is likely the most cost‐effective approach to investigate CNVs in these genes in low‐risk populations, with MLPA being reserved as an orthogonal confirmatory test.
- 15 January 2023
- Published by Wiley in Clinical Genetics
- Vol. 103 (5) , 580-584
Copy number variations in SPAST and ATL1 are rare among Brazilians
Copy number variations (CNV) may represent a significant proportion of SPG4 and SPG3A diagnosis, the most frequent autosomal dominant subtypes of hereditary spastic paraplegias (HSP). We aimed to assess the frequency of CNVs in SPAST and ATL1 and to update the molecular epidemiology of HSP families in southern Brazil. A cohort study that included 95 Brazilian index cases with clinical suspicion of HSP was conducted between April 2011 and September 2022. Multiplex Ligation Dependent Probe Amplification (MLPA) was performed in 41 cases without defined diagnosis by different massive parallel sequencing techniques (MPS). Diagnosis was obtained in 57/95 (60%) index cases, 15/57 (26.3%) being SPG4. Most frequent autosomal recessive HSP subtypes were SPG7 followed by SPG11, SPG76 and cerebrotendinous xanthomatosis. No CNVs in SPAST and ATL1 were found. Copy number variations are rare among SPG4 and SPG3A families in Brazil. Considering the possibility of CNVs detection by specific algorithms with MPS data, we consider that this is likely the most cost‐effective approach to investigate CNVs in these genes in low‐risk populations, with MLPA being reserved as an orthogonal confirmatory test.
- Open Access
- 26 October 2022
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 8 (6) , e200024
Increased Serum Levels of miR-125b and miR-132 in Fragile X Syndrome
Background and Objectives Fragile X syndrome (FXS) is a neurodevelopmental disorder, identified as the most common cause of hereditary intellectual disability and monogenic cause of autism spectrum disorders (ASDs), caused by the loss of fragile X mental retardation protein (FMRP). FMRP is an RNA-binding protein, a regulator of translation that plays an important role in neurodevelopment, and its loss causes cognitive and behavioral deficits. MicroRNAs (miRNAs) are small molecules that regulate gene expression in diverse biological processes. Previous studies found that the interaction of FMRP with miR-125b and miR-132 regulates the maturation and synaptic plasticity in animal models and miRNA dysregulation plays a role in the pathophysiology of FXS. The present study aimed to analyze the expression of miR-125b-5p and miR-132-3p in the serum of patients with FXS. Methods The expressions of circulating miRNAs were studied in the serum of 10 patients with FXS and 20 controls using the real-time quantitative retrotranscribed method analyzed by relative quantification. Receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC) were generated to assess the diagnostic values of the miRNAs. Results We found that both miR-125b and miR-132 were increased in the serum of patients with FXS compared with controls and likely involved with FMRP loss. The AUC (95% confidence interval) of miR-125b and miR-132 was 0.94 (0.86–1.0) and 0.89 (0.77–1.0), respectively. Databases allowed for the identification of possible target genes for miR-125b and miR-132, whose products play an important role in the homeostasis of the nervous system. Discussion Our results indicate that serum miR-125b and miR-132 may serve as potential biomarkers for FXS. The increased expression of circulating miR-125b and miR-132 seems to be associated with the genotype of FXS. Predicted gene targets of the differentially regulated miRNAs are involved in cognitive performance and ASD phenotype. Classification of Evidence This study provides Class III evidence that miR-125b and miR-132 distinguish men with FXS from normal controls.
- 26 October 2022
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 8 (6) , e200024
Open AccessIncreased Serum Levels of miR-125b and miR-132 in Fragile X Syndrome
Background and Objectives Fragile X syndrome (FXS) is a neurodevelopmental disorder, identified as the most common cause of hereditary intellectual disability and monogenic cause of autism spectrum disorders (ASDs), caused by the loss of fragile X mental retardation protein (FMRP). FMRP is an RNA-binding protein, a regulator of translation that plays an important role in neurodevelopment, and its loss causes cognitive and behavioral deficits. MicroRNAs (miRNAs) are small molecules that regulate gene expression in diverse biological processes. Previous studies found that the interaction of FMRP with miR-125b and miR-132 regulates the maturation and synaptic plasticity in animal models and miRNA dysregulation plays a role in the pathophysiology of FXS. The present study aimed to analyze the expression of miR-125b-5p and miR-132-3p in the serum of patients with FXS. Methods The expressions of circulating miRNAs were studied in the serum of 10 patients with FXS and 20 controls using the real-time quantitative retrotranscribed method analyzed by relative quantification. Receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC) were generated to assess the diagnostic values of the miRNAs. Results We found that both miR-125b and miR-132 were increased in the serum of patients with FXS compared with controls and likely involved with FMRP loss. The AUC (95% confidence interval) of miR-125b and miR-132 was 0.94 (0.86–1.0) and 0.89 (0.77–1.0), respectively. Databases allowed for the identification of possible target genes for miR-125b and miR-132, whose products play an important role in the homeostasis of the nervous system. Discussion Our results indicate that serum miR-125b and miR-132 may serve as potential biomarkers for FXS. The increased expression of circulating miR-125b and miR-132 seems to be associated with the genotype of FXS. Predicted gene targets of the differentially regulated miRNAs are involved in cognitive performance and ASD phenotype. Classification of Evidence This study provides Class III evidence that miR-125b and miR-132 distinguish men with FXS from normal controls.
- Open Access
- 20 May 2022
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 89 (2) , 254-263
High microbiome variability in pediatric tracheostomy cannulas in patients with similar clinical characteristics
- 20 May 2022
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 89 (2) , 254-263
Open AccessHigh microbiome variability in pediatric tracheostomy cannulas in patients with similar clinical characteristics
- Open Access
- 1 March 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 96 (2) , 155-162
Painel de genes para o diagnóstico da epidermólise bolhosa: proposta de abordagem viável e eficiente
- 1 March 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 96 (2) , 155-162
Open AccessPainel de genes para o diagnóstico da epidermólise bolhosa: proposta de abordagem viável e eficiente